Advances in nanoparticles-based approaches in cancer theranostics
In recent years, the incidence and mortality rate of cancer is raising worldwide. Traditional approaches for cancer patient management including surgery, chemotherapy, radiotherapy, and targeted therapies provide unsatisfactory results and are often associated with adverse reactions. Over the last f...
| 出版年: | OpenNano |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Elsevier
2023-07-01
|
| 主題: | |
| オンライン・アクセス: | http://www.sciencedirect.com/science/article/pii/S2352952023000312 |
| _version_ | 1851842221632913408 |
|---|---|
| author | Muhammad Akmal Raheem Muhammad Ajwad Rahim Ijaz Gul Xiaoyun Zhong Chufan Xiao Haihui Zhang Jiazhang Wei Qian He Muhammad Hassan Can Yang Zhang Dongmei Yu Vijay Pandey Ke Du Runming Wang Sanyang Han Yuxing Han Peiwu Qin |
| author_facet | Muhammad Akmal Raheem Muhammad Ajwad Rahim Ijaz Gul Xiaoyun Zhong Chufan Xiao Haihui Zhang Jiazhang Wei Qian He Muhammad Hassan Can Yang Zhang Dongmei Yu Vijay Pandey Ke Du Runming Wang Sanyang Han Yuxing Han Peiwu Qin |
| author_sort | Muhammad Akmal Raheem |
| collection | DOAJ |
| container_title | OpenNano |
| description | In recent years, the incidence and mortality rate of cancer is raising worldwide. Traditional approaches for cancer patient management including surgery, chemotherapy, radiotherapy, and targeted therapies provide unsatisfactory results and are often associated with adverse reactions. Over the last few decades, nanotechnology has been a rapidly emerging area of theragnostic in clinical research. It plays a vital role as a bridge between the science and technology of miscellaneous nanoparticles (NPs) and nanomedicine. In general, NPs with a range of sizes of 1–100 nm are thought to be acceptable for cancer medications. NPs may enhance the consistency and solubility of therapeutic drugs to obtain site-specific targeting, controlled release, and safe for healthy organs. NPs have the benefit of pathophysiological properties, enhanced permeability and retention (EPR) effects, and an advantage in cancer targeting. Furthermore, theranostic nanoparticles have been established having incorporated diagnostics and therapy in a single system that might provide more personalized treatment with optimal doses and monitoring the distribution, targeting, and response to therapy by using imaging tools. In this review, we have discussed the classes of nanoparticles, targeting approaches, and implications of NPs for cancer theranostics with recent examples. |
| format | Article |
| id | doaj-art-e3da40a4e9d24b88846d2e992355f9ca |
| institution | Directory of Open Access Journals |
| issn | 2352-9520 |
| language | English |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| spelling | doaj-art-e3da40a4e9d24b88846d2e992355f9ca2025-08-19T22:27:54ZengElsevierOpenNano2352-95202023-07-011210015210.1016/j.onano.2023.100152Advances in nanoparticles-based approaches in cancer theranosticsMuhammad Akmal Raheem0Muhammad Ajwad Rahim1Ijaz Gul2Xiaoyun Zhong3Chufan Xiao4Haihui Zhang5Jiazhang Wei6Qian He7Muhammad Hassan8Can Yang Zhang9Dongmei Yu10Vijay Pandey11Ke Du12Runming Wang13Sanyang Han14Yuxing Han15Peiwu Qin16Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaDepartment of Zoology, Ghazi University, D. G Khan 32200, PakistanInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaShenzhen Children's Hospital, Guangdong, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaSchool of Mechanical, Electrical & Information Engineering, Shandong University, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaDepartment of Chemical and Environmental Engineering, University of California, Riverside, CA, USAInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR China; Corresponding author at: Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China.In recent years, the incidence and mortality rate of cancer is raising worldwide. Traditional approaches for cancer patient management including surgery, chemotherapy, radiotherapy, and targeted therapies provide unsatisfactory results and are often associated with adverse reactions. Over the last few decades, nanotechnology has been a rapidly emerging area of theragnostic in clinical research. It plays a vital role as a bridge between the science and technology of miscellaneous nanoparticles (NPs) and nanomedicine. In general, NPs with a range of sizes of 1–100 nm are thought to be acceptable for cancer medications. NPs may enhance the consistency and solubility of therapeutic drugs to obtain site-specific targeting, controlled release, and safe for healthy organs. NPs have the benefit of pathophysiological properties, enhanced permeability and retention (EPR) effects, and an advantage in cancer targeting. Furthermore, theranostic nanoparticles have been established having incorporated diagnostics and therapy in a single system that might provide more personalized treatment with optimal doses and monitoring the distribution, targeting, and response to therapy by using imaging tools. In this review, we have discussed the classes of nanoparticles, targeting approaches, and implications of NPs for cancer theranostics with recent examples.http://www.sciencedirect.com/science/article/pii/S2352952023000312CancerNanotechnologyNanomedicineNanoparticlesTheranostics |
| spellingShingle | Muhammad Akmal Raheem Muhammad Ajwad Rahim Ijaz Gul Xiaoyun Zhong Chufan Xiao Haihui Zhang Jiazhang Wei Qian He Muhammad Hassan Can Yang Zhang Dongmei Yu Vijay Pandey Ke Du Runming Wang Sanyang Han Yuxing Han Peiwu Qin Advances in nanoparticles-based approaches in cancer theranostics Cancer Nanotechnology Nanomedicine Nanoparticles Theranostics |
| title | Advances in nanoparticles-based approaches in cancer theranostics |
| title_full | Advances in nanoparticles-based approaches in cancer theranostics |
| title_fullStr | Advances in nanoparticles-based approaches in cancer theranostics |
| title_full_unstemmed | Advances in nanoparticles-based approaches in cancer theranostics |
| title_short | Advances in nanoparticles-based approaches in cancer theranostics |
| title_sort | advances in nanoparticles based approaches in cancer theranostics |
| topic | Cancer Nanotechnology Nanomedicine Nanoparticles Theranostics |
| url | http://www.sciencedirect.com/science/article/pii/S2352952023000312 |
| work_keys_str_mv | AT muhammadakmalraheem advancesinnanoparticlesbasedapproachesincancertheranostics AT muhammadajwadrahim advancesinnanoparticlesbasedapproachesincancertheranostics AT ijazgul advancesinnanoparticlesbasedapproachesincancertheranostics AT xiaoyunzhong advancesinnanoparticlesbasedapproachesincancertheranostics AT chufanxiao advancesinnanoparticlesbasedapproachesincancertheranostics AT haihuizhang advancesinnanoparticlesbasedapproachesincancertheranostics AT jiazhangwei advancesinnanoparticlesbasedapproachesincancertheranostics AT qianhe advancesinnanoparticlesbasedapproachesincancertheranostics AT muhammadhassan advancesinnanoparticlesbasedapproachesincancertheranostics AT canyangzhang advancesinnanoparticlesbasedapproachesincancertheranostics AT dongmeiyu advancesinnanoparticlesbasedapproachesincancertheranostics AT vijaypandey advancesinnanoparticlesbasedapproachesincancertheranostics AT kedu advancesinnanoparticlesbasedapproachesincancertheranostics AT runmingwang advancesinnanoparticlesbasedapproachesincancertheranostics AT sanyanghan advancesinnanoparticlesbasedapproachesincancertheranostics AT yuxinghan advancesinnanoparticlesbasedapproachesincancertheranostics AT peiwuqin advancesinnanoparticlesbasedapproachesincancertheranostics |
